ArticleApoptosis : an international journal on programmed cell death2024
Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma.
Article in Apoptosis : an international journal on programmed cell death, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Limitations of nomogram models in predicting survival outcomes for glioma patients.Frontiers in immunology · 2025Pooled it
- Prognostic and Immunological Significance of TIPARP in Pancreatic Cancer.Digestive diseases and sciences · 2026Article
- Integrative Machine-Learning Molecular Subtyping and Risk Scores of Circadian Rhythm-Related Prognostic Signatures in Colorectal Cancer.Journal of gastrointestinal cancer · 2026Article
- Development and validation of a cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response in breast cancer: a retrospective analysis of TCGA data.Translational cancer research · 2026Article
- Cuproptosis scoring system identifies novel molecular subtypes and modulates biological behavior in breast cancer.Discover oncology · 2025Article
- Identification of hub six interferon alpha response genes and immune cell infiltration characteristics in low-grade glioma.Scientific reports · 2025Article
- Bioinformatics-based identification of key genes for Olaparib resistance in breast cancer: prognostic implications and therapeutic relevance.Discover oncology · 2025Article
- Comprehensive analysis of phagocytosis regulatory genes in bladder cancer: implications for prognosis and immunotherapy.Frontiers in molecular biosciences · 2025Article
- Characterization of Cuproptosis-Related LncRNAs Prognostic Signature and Identification of LINC02285 as a Novel Biomarker for Ovarian Cancer.Journal of inflammation research · 2025Article
- LncRNA-driven programmed cell death networks: new therapeutic targets for neurological disorders.Frontiers in molecular neuroscience · 2025Review
- Novel immune cross-talk between inflammatory bowel disease and IgA nephropathy.Renal failure · 2024Article
- A novel necroptosis-related genes signature to predict prognosis and treatment response in bladder cancer.Frontiers in molecular biosciences · 2024Article
- Cuproptosis in glioblastoma: unveiling a novel prognostic model and therapeutic potential.Frontiers in oncology · 2024Article
- Comprehending the cuproptosis and cancer-immunity cycle network: delving into the immune landscape and its predictive role in breast cancer immunotherapy responses and clinical endpoints.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
Cuprotosis, an emerging mode of cell death, has recently caught the attention of researchers worldwide. However, its impact on low-grade glioma (LGG) patients has not been fully explored. To gain a deeper insight into the relationship between cuprotosis and LGG patients' prognosis, we conducted this study in which LGG patients were divided into two clusters based on the expression of 18 cuprotosis-related genes. We found that LGG patients in cluster A had better prognosis than those in cluster B. The two clusters also differed in terms of immune cell infiltration and biological functions. Moreover, we identified differentially expressed genes (DEGs) between the two clusters and developed a cuprotosis-related prognostic signature through the least absolute shrinkage and selection operator (LASSO) analysis in the TCGA training cohort. This signature divided LGG patients into high- and low-risk groups, with the high-risk group having significantly shorter overall survival (OS) time than the low-risk group. Its predictive reliability for prognosis in LGG patients was confirmed by the TCGA internal validation cohort, CGGA325 cohort and CGGA693 cohort. Additionally, a nomogram was used to predict the 1-, 3-, and 5-year OS rates of each patient. The analysis of immune checkpoints and tumor mutation burden (TMB) has revealed that individuals belonging to high-risk groups have a greater chance of benefiting from immunotherapy. Functional experiments confirmed that interfering with the signature gene TNFRSF11B inhibited LGG cell proliferation and migration. Overall, this study shed light on the importance of cuprotosis in LGG patient prognosis. The cuprotosis-related prognostic signature is a reliable predictor for patient outcomes and immunotherapeutic response and can help to develop new therapies for LGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.